Clinical Trial Update: Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety and tolerability of intraperitoneal nivolumab after extensive debulking surgery and HIPEC in patients with advanc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED